Home › Cases › The Platelet Transfusion Request
TTP
The Platelet Transfusion Request
6 questions
Question 1 · The Bleep
Correct answer: Do not transfuse. Platelet transfusion is contraindicated in TTP and can precipitate arterial thrombosis and death — escalate to haematology now
Why
Platelet transfusion is contraindicated in TTP. The pathway states that it can precipitate arterial thrombosis and death.
- TTP is a platelet-consumptive thrombotic disorder — the platelets are being consumed making microvascular thrombi. Adding more platelets adds fuel
- The usual transfusion thresholds you apply to other causes of thrombocytopaenia do not apply here, and applying them by reflex is the danger
- Only consider it if there is life-threatening haemorrhage AND after senior haematology authorisation
- Gum bleeding is not life-threatening haemorrhage
- A smaller dose is not a safer version of a contraindicated treatment
Key point
Platelets in TTP can cause arterial thrombosis and death. Gum bleeding is not a reason. Escalate instead.
Question 2 · Saying It
Correct answer: State the contraindication clearly, and contact haematology directly to confirm the plan
Why
Say it plainly, and get haematology on the phone.
- "Platelet transfusion is contraindicated in TTP — it can cause arterial thrombosis. Can we speak to haematology?" is a complete and professional sentence
- Seniority does not override a specific contraindication, and the registrar may simply not have made the connection with a rare diagnosis
- Contacting haematology resolves it without it becoming a disagreement — they are already involved in a patient awaiting exchange
- Silently not doing it is unsafe — someone else will action it, and nobody will have learned anything
Key point
Name the contraindication, then get the specialist on the phone. Silent non-compliance is not a safety behaviour.
Question 3 · What He Actually Needs
Correct answer: Plasma exchange started urgently — within 4–8 hours of diagnosis — with prednisolone 1mg/kg/day
Why
The treatment for the bleeding is the treatment for the disease: plasma exchange, urgently.
- 1.5x plasma volume daily with FFP replacement, started within 4–8 hours of diagnosis, plus prednisolone 1mg/kg/day (max 60mg)
- The platelet count rises as the process is treated. Nothing else will correct it
- Caplacizumab alongside the first exchange where available
- FFP infusion is not a substitute for exchange — it supplies ADAMTS13 but does not remove the inhibitor. It is a stop-gap while apheresis is arranged, not an alternative
- Local measures are reasonable adjuncts but do not address why he is bleeding
Key point
Exchange is the treatment for the bleeding too. The count rises when the disease is treated, not when platelets are given.
Question 4 · Deteriorating
Correct answer: Neurological deterioration despite ongoing exchange is an escalation trigger — urgent haematology and critical care input
Why
Neurological deterioration despite ongoing plasma exchange is first on the escalation list.
- Urgent haematology and critical care involvement. Options include intensifying exchange, and caplacizumab if not already running
- Refractory disease — failure to respond after five exchanges — is an indication for rituximab, either 375mg/m² weekly × 4 or the low-dose 100mg BSH 2023 protocol
- Imaging is likely to be needed and a seizure with falling GCS warrants a CT — but it is arranged alongside escalation, not instead of it
- Deterioration on treatment is never simply expected
Key point
Neurological deterioration on exchange means escalate. Refractory after five exchanges → rituximab.
Question 5 · Caplacizumab
Correct answer: It blocks the platelet–von Willebrand factor interaction; monitor for bleeding
Why
Caplacizumab blocks the platelet–vWF interaction, preventing the platelet-rich microthrombi that cause the organ damage.
- 10mg IV before the first exchange, then 10mg SC daily, started alongside the first exchange, and continued for 30 days after the last exchange
- Monitor for bleeding — the anti-vWF effect is the mechanism and the side effect
- It does not replace ADAMTS13 — that is what the FFP in the exchange does
- Suppressing autoantibody production is what rituximab and prednisolone do, by depleting B cells and dampening the immune response respectively
Key point
Caplacizumab blocks platelet–vWF. Watch for bleeding. It is not a replacement for exchange or for ADAMTS13.
Question 6 · After Remission
Correct answer: Exacerbation within 30 days of stopping exchange — recheck ADAMTS13
Why
Watch for exacerbation within 30 days of stopping plasma exchange, and recheck ADAMTS13.
- A normal platelet count does not mean the underlying ADAMTS13 deficiency and inhibitor have resolved. A persistently low activity predicts relapse
- This is also why caplacizumab continues for 30 days after the final exchange
- Relapse is an indication for rituximab, as is refractory disease
- Stopping all monitoring at remission is exactly how an exacerbation is missed
- Rebound thrombocytosis is not the concern here
Key point
The 30 days after the last exchange are the risky window. Recheck ADAMTS13 — a low level predicts relapse.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.